Immunogenicity of BNT162b2 as a first booster after a ChAdOx1 primary series in a Thai geriatric population living with frailty

IF 4.3 3区医学 Q1 GERIATRICS & GERONTOLOGY Journal of Nutrition Health & Aging Pub Date : 2024-07-17 DOI:10.1016/j.jnha.2024.100315

{"title":"Immunogenicity of BNT162b2 as a first booster after a ChAdOx1 primary series in a Thai geriatric population living with frailty","authors":"","doi":"10.1016/j.jnha.2024.100315","DOIUrl":null,"url":null,"abstract":"<div><h3>Objectives</h3><p>Impact of frailty towards immunogenicity and reactogenicity of BNT162b2 boosters administered via intramuscular or intradermal routes in a Thai geriatric population</p></div><div><h3>Design</h3><p>Prospective, randomized, open-labeled.</p></div><div><h3>Setting</h3><p>Siriraj Hospital, Thailand.</p></div><div><h3>Participants</h3><p>Geriatric adults aged ≥65 years.</p></div><div><h3>Intervention</h3><p>10 μg intradermal or 30 μg intramuscular BNT162b2 (Pfizer-BioNTech).</p></div><div><h3>Measurements</h3><p>Anti-SARS-CoV-2 receptor binding domain IgG, neutralizing antibodies (NAb), and interferon-gamma producing cells against Wuhan and Omicron BA.4/5. Analyses were stratified based on participants’ Clinical Frailty Scale.</p></div><div><h3>Results</h3><p>A total of 139 participants were included in the analysis. Two-four weeks post-booster administration, NAb titers against Wuhan but not Omicron BA.4/5 were significantly lower among frail participants than non-frail participants who received intramuscular administration. Spike-specific T cell responses were similar for frail and non-frail participants, regardless of administration route. Frail participants who received intradermal BNT162b2 had fewer local adverse events (AEs), but higher systemic AEs than non-frail participants.</p></div><div><h3>Conclusion</h3><p>Similar immune responses across vaccine routes warrants further evaluation of intradermal BNT162b2 in frail geriatric populations. Frail participants may be more sensitive to reporting systemic AEs.</p></div><div><h3>Registration of clinical trials</h3><p>The parent study was registered under the Thai Clinical Trials Registry (TCTR20220112002).</p></div>","PeriodicalId":54778,"journal":{"name":"Journal of Nutrition Health & Aging","volume":null,"pages":null},"PeriodicalIF":4.3000,"publicationDate":"2024-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1279770724004020/pdfft?md5=608a02641f6454280eea7645977239b6&pid=1-s2.0-S1279770724004020-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Nutrition Health & Aging","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1279770724004020","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GERIATRICS & GERONTOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives

Impact of frailty towards immunogenicity and reactogenicity of BNT162b2 boosters administered via intramuscular or intradermal routes in a Thai geriatric population

Design

Prospective, randomized, open-labeled.

Setting

Siriraj Hospital, Thailand.

Participants

Geriatric adults aged ≥65 years.

Intervention

10 μg intradermal or 30 μg intramuscular BNT162b2 (Pfizer-BioNTech).

Measurements

Anti-SARS-CoV-2 receptor binding domain IgG, neutralizing antibodies (NAb), and interferon-gamma producing cells against Wuhan and Omicron BA.4/5. Analyses were stratified based on participants’ Clinical Frailty Scale.

Results

A total of 139 participants were included in the analysis. Two-four weeks post-booster administration, NAb titers against Wuhan but not Omicron BA.4/5 were significantly lower among frail participants than non-frail participants who received intramuscular administration. Spike-specific T cell responses were similar for frail and non-frail participants, regardless of administration route. Frail participants who received intradermal BNT162b2 had fewer local adverse events (AEs), but higher systemic AEs than non-frail participants.

Conclusion

Similar immune responses across vaccine routes warrants further evaluation of intradermal BNT162b2 in frail geriatric populations. Frail participants may be more sensitive to reporting systemic AEs.

Registration of clinical trials

The parent study was registered under the Thai Clinical Trials Registry (TCTR20220112002).

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

BNT162b2 作为 ChAdOx1 初级系列治疗后的第一支增强剂在泰国老年体弱人群中的免疫原性

目的在泰国老年人群中通过肌肉或皮内途径注射 BNT162b2 增强剂时，体弱对免疫原性和反应原性的影响。干预措施10 μg 皮内或 30 μg 肌肉注射 BNT162b2（辉瑞公司-BioNTech）.测量抗 SARS-CoV-2 受体结合域 IgG、中和抗体（NAb）以及针对武汉和 Omicron BA.4 的γ干扰素产生细胞。/5.根据参与者的临床虚弱量表进行分层分析。在注射加强剂后两周至四周，体弱者对武汉病毒的NAb滴度明显低于肌肉注射的非体弱者，但对Omicron BA.4/5的NAb滴度则没有明显降低。无论给药途径如何，体弱者和非体弱者的尖峰特异性 T 细胞反应相似。接受皮内注射 BNT162b2 的体弱者的局部不良反应（AEs）少于非体弱者，但全身不良反应（AEs）高于非体弱者。体弱参与者可能对报告全身性 AEs 更为敏感。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Journal of Nutrition Health & Aging 医学-老年医学

CiteScore

7.80

自引率

3.40%

发文量

136

审稿时长

4-8 weeks

期刊介绍： There is increasing scientific and clinical interest in the interactions of nutrition and health as part of the aging process. This interest is due to the important role that nutrition plays throughout the life span. This role affects the growth and development of the body during childhood, affects the risk of acute and chronic diseases, the maintenance of physiological processes and the biological process of aging. A major aim of "The Journal of Nutrition, Health & Aging" is to contribute to the improvement of knowledge regarding the relationships between nutrition and the aging process from birth to old age.